Myriad Genetics, Inc. Forecast, price target & analysts
Myriad Genetics, Inc. Target price 2025 - Analyst rating & recommendation
Myriad Genetics, Inc. Classifications & Recommendation:
Myriad Genetics, Inc. Price Target
| Target Price | $7.40 |
| Price | $4.45 |
| Potential |
66.29%
register free of charge
|
| Number of Estimates | 15 |
|
15 Analysts have issued a price target Myriad Genetics, Inc. 2026 .
The average Myriad Genetics, Inc. target price is $7.40.
This is
66.29%
register free of charge
$18.00
304.49%
register free of charge
$4.00
10.11%
register free of charge
|
|
| A rating was issued by 17 analysts: 4 Analysts recommend Myriad Genetics, Inc. to buy, 9 to hold and 4 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Myriad Genetics, Inc. stock has an average upside potential 2026 of
66.29%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 837.60 | 810.53 |
| 11.21% | 3.23% | |
| EBITDA Margin | -3.20% | 2.66% |
| 67.87% | 185.69% | |
| Net Margin | -15.52% | -7.59% |
| 60.13% | 51.10% |
17 Analysts have issued a sales forecast Myriad Genetics, Inc. 2025 . The average Myriad Genetics, Inc. sales estimate is
This results in the following potential growth metrics:
13 Analysts have issued an Myriad Genetics, Inc. EBITDA forecast 2025. The average Myriad Genetics, Inc. EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
8 Myriad Genetics, Inc. Analysts have issued a net profit forecast 2025. The average Myriad Genetics, Inc. net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.41 | -0.67 |
| 55.66% | 52.48% | |
| P/E | negative | |
| EV/Sales | 0.59 |
8 Analysts have issued a Myriad Genetics, Inc. forecast for earnings per share. The average Myriad Genetics, Inc. EPS is
This results in the following potential growth metrics and future valuations:
Myriad Genetics, Inc....
Current Myriad Genetics, Inc. Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| Piper Sandler |
Locked
➜
Locked
|
Locked | May 15 2025 |
| Wells Fargo |
Locked
➜
Locked
|
Locked | May 08 2025 |
| UBS |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Raymond James |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | May 07 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Apr 17 2025 |
| Guggenheim |
Locked
➜
Locked
|
Locked | Apr 09 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
Piper Sandler:
Locked
➜
Locked
|
May 15 2025 |
|
Locked
Wells Fargo:
Locked
➜
Locked
|
May 08 2025 |
|
Locked
UBS:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Raymond James:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
May 07 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Apr 17 2025 |
|
Locked
Guggenheim:
Locked
➜
Locked
|
Apr 09 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
